PROCARE - PROstate Cancer Real World Evidence Registry

Inclusion Criteria:

• Adult prostate cancer patients (age ≥18 years).

• Diagnosis at time of study inclusion Cohort 1: biochemical recurrence (BCR) afterlocal curative intended treatment (e.g. radical prostatectomy, radiotherapy of theprostate or combination thereof) Cohort 2: non-metastatic castration-resistantprostate cancer (nmCRPC) or Cohort 3: metastatic hormone sensitive prostate cancer (mHSPC) or Cohort 4: metastatic castration-resistant prostate cancer (mCRPC) (irrespective of treatment choice, treatment line)

• Patients who will receive a new line of systemic therapy at the time of study entryor up to 4 weeks thereafter. Regarding Cohort 4 this includes patients with a newdiagnosis of mCRPC (=first line mCRPC) after either treatment for mHSPC ornon-metastatic CRPC as well as patients with prior mCRPC treatments (2nd, 3rd, …line).

• For Cohorts 1, 2 and 3: Disease proven by clinical measures (i.e. standard imaging)to be either unsuitable for local salvage treatment (e.g. surgery, radiotherapy) orlocal treatment is declined by the patient.

• Patients, who are able and willing to sign the informed consent form

Exclusion Criteria:

• Patients who are not eligible for observation due to severe comorbidities or unavailability according to the treating physician